Meeting
2016 ASCO Annual Meeting
Circulating neuroendocrine transcripts and gene cluster analysis to predict the efficacy of peptide radioreceptor therapy.
Authors
Lisa Bodei
European Institute of Oncology, Milan, Italy
Lisa Bodei , Mark S. Kidd , Aviral Singh , Ignat Drozdov , Stefano Severi , Sylvia Nicolini , Richard P. Baum , Giovanni Paganelli , Dik J. Kwekkeboom , Eric Krenning , Irvin Mark Modlin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Citation
J Clin Oncol 34, 2016 (suppl; abstr 4098)
DOI
10.1200/JCO.2016.34.15_suppl.4098
Abstract #
4098
Poster Bd #
90
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Blood measurements of neuroendocrine tumor (NET) transcripts and gene cluster analysis to predict efficacy of peptide radioreceptor therapy.
First Author: Lisa Bodei
Poster
2023 ASCO Gastrointestinal Cancers Symposium
ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
First Author: Aman Chauhan
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Real-world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy.
First Author: Stijn Hentzen
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Pivotal phase III COMPOSE trial will compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors.
First Author: Thorvardur Ragnar Halfdanarson